The Guardian view on de-extinction: Jurassic Park may be becoming reality
By Editorial,
The Guardian
| 08. 19. 2022
We should be keeping endangered species alive rather than bringing animals back from extinction
"tasmanian tiger" by nicolas.boullosa is licensed under CC BY 2.0.
The last official sighting of a Tasmanian tiger in the wild occurred in 1930, when it was shot by a farmer. The marsupials, formally known as thylacines, were hunted to extinction by European settlers who considered them a threat to their sheep and poultry. However, the 6ft-long creatures may reappear if a group of biotechnologists have their way.
The company Colossal Biosciences, along with researchers from the University of Melbourne, plans to “de-extinct” the thylacine by using gene-editing technology. Australia has the fastest rate of mammal extinction in the world; disappearances are down to the arrival of foreign species and wildfires linked to the climate crisis. Scientists argue that in Tasmania the loss of the thylacine left the numbers of smaller marsupials unchecked, leading to over-grazing and threatening a fragile ecological balance.
If it all sounds like a plot line from Jurassic Park, then that is because the science behind the resurrection plan provided the movie’s inspiration. Last year Colossal, co-founded by a Harvard geneticist, raised...
Related Articles
By Maggie Astor, The New York Times | 06.23.2026
Every year, patients undergo millions of in vitro fertilization procedures worldwide. Only a minority result in a live birth.
In an effort to improve the odds, scientists have developed an array of “add-ons” that could in theory identify the most...
By Carl Zimmer and Catrin Einhorn, The New York Times | 06.25.2026
The Trump administration and a company that is promising to bring long-gone animals back from extinction announced a partnership on Thursday to preserve cells, tissue and DNA from threatened and endangered species.
The company, Colossal Biosciences, said its goal was...
By Marisa Flook , BioNews | 06.29.2026
An anti-ageing gene therapy not approved by the US Food and Drug Administration (FDA) is set to be offered by an American company at overseas clinics outside of US jurisdiction.
The treatment, developed by Minicircle from Austin, Texas, uses a...
By Philip Ball , Nature | 06.17.2026
Our genomes are full of mutations that have the potential to damage our health or even kill us. Yet most of them rarely cause problems. Why? It’s partly thanks to a family of proteins that mask, or ‘buffer’, the ill...